拜新同联合拉贝洛尔治疗早期妊娠合并高血压的疗效及安全性分析  

Worship the efficacy and safety of hypertension in early pregnancy with new labetalol treatment

作　　者：李薇薇[1] 赵义勇 

机构地区：[1]新疆昌吉州人民医院,新疆831100

出　　处：《实用妇科内分泌电子杂志》2017年第21期26-27,共2页Electronic Journal of Practical Gynecological Endocrinology

摘　　要：目的研究拜新同联合拉贝洛尔治疗早期妊娠合并高血压的疗效以及安全性。方法于2016年4月~2017年5月在我院就诊的早期妊娠合并高血压孕妇中选出130例,根据用药方法不同分组,对照组孕妇给予拜新同+氢氯噻嗪片治疗;观察组孕妇给予拜新同+拉贝洛尔治疗。结果治疗3个月、6个月,观察组患者的血压达标率与对照组,差异无统计学意义(P>0.05);观察组孕妇治疗期间不良反应发生率6.35%低于对照组孕妇的19.40%,差异有统计学意义(P<0.05)。结论拜新同联合拉贝洛尔治疗早期妊娠合并高血压降压效果确切,且用药安全性高,有利于保证母儿健康,值得推广。Objective To study the effect of early pregnancy with hypertension thanks to new with the United labetalol treatment and safety. Methods In April 2016 - 2017 year in May in our hospital for early pregnancy with hypertension in pregnant women selected 130 cases, according to different methods of treatment group, the control group of pregnant women given Adalat ＋ Hydrochlorothiazide Tablets treatment; the observation group was given Adalat ＋ labetalol treatment. Results After 3 months and 6 months treatment, the blood pressure compliance rate of the observation group was not significantly different from that of the control group（P〉0.05）; the observation group the adverse reaction rate was 6.35% lower than that of the control group of pregnant women during 19.40%,（P〈0.05）. Conclusion Adalat combined with labetalol in treatment of early pregnancy with antihypertensive effect, and medication safety, to ensure the health of mother and fetus, and is worthy of promotion.

关 键 词：拜新同 拉贝洛尔 氢氯噻嗪 早期妊娠 高血压 

分 类 号：R714.246[医药卫生—妇产科学]